Published • loading... • Updated
Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom
Summary by ts2.tech
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom
Hims & Hers Health shares rose 10.2% to $28.27 on Friday ahead of first-quarter results due Monday. Analysts expect Q1 revenue near $616.9 million and earnings of 3 cents per share. The company recently reached a deal with Novo Nordisk to offer Ozempic and Wegovy, and added Eli Lilly’s Zepbound and Foundayo to its platform. The FDA is considering tighter rules on compounding GLP-1 drugs. The post Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
